
ERIS Lifescience Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Domestic Branded Formulations (DBF) base business is tracking 9-10% growth for FY25, driven mainly by new product launches in H2.
- Insulin segment expected to grow strongly at 18-20% CAGR over the next 2-3 years despite some supply challenges.
- Swiss Parenterals business targeting Rs. 330 crore revenue this year, around 15% growth, with new segments like injectable CDMO and oral solids exports contributing from FY26 onwards.
- Injectable India business currently Rs. 7 crore/month, expected to improve significantly next year.
- Launch of GLP-1 drugs (Liraglutide and upcoming Semaglutide in 2026) anticipated to be a game changer with substantial market growth.
- Vertical integration through Levim partnership expected to accelerate biologics pipeline and production capacity by mid-next year, enhancing long-term growth.
- Overall consolidated revenue guidance for FY25 is Rs. 3,000 crore with 35% EBITDA margin, with branded formulations at Rs. 2,600 crore and 36% margin.
See what ERIS Lifescience management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned new fundraising through debt or equity in the provided transcript.
- The company is ahead of schedule in terms of debt repayment, with net debt at Rs. 2,500 crores at the end of Q2, against a year-end target of Rs. 2,600 crores.
- The focus is on strengthening the balance sheet and reducing debt rather than raising new debt.
- Capital expenditure guidance is Rs. 100-120 crores, and a Rs. 54 crore investment in Levim has been made for a 30% equity stake.
- No indications of raising funds through equity in the near term were stated.
- The company appears focused on organic growth, acquisitions (e.g., Biocon businesses), and strategic partnerships funded with internal resources or planned investments.
See what ERIS Lifescience management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned capital expenditure (CAPEX) of Rs. 100 to 120 crores for the financial year.
- Strategic investment of Rs. 54 crores for a 30% equity stake in Levim Lifetech.
- Levim investment aims to build a vertically integrated biologics presence and access to an exciting biologics product pipeline.
- Large-scale bulk manufacturing facility at Levim to be commissioned by mid next year.
- Levim's existing commercial products include Liraglutide API, Streptokinase, and Pegaspargase.
- New business segments such as Injectable CDMO for European markets and Oral Solid Dose exports planned to start contributing from FY 2026 onwards.
- Bhopal site starting insulin vial manufacturing from next month, expected to improve margins from Q4 FY25 / Q1 FY26.
Track ERIS Lifescience — get its next earnings analysis in your feed
How does ERIS Lifescience rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does ERIS Lifescience rank in Pharmaceuticals & Biotechnology?
Compare ERIS Lifescience against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What ERIS Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem